SuperSonic Imagine, the innovative medical imaging company based in Aix-en-Provence, France has unveiled some of the results of the largest clinical breast study ever undertaken in ultrasound imaging. The worldwide multicenter study, involving top clinicians in the breast radiology community, is assessing the clinical benefits of ShearWave™ Elastography in the ultrasonic evaluation of breast lesions.
The study has two objectives: The first is to demonstrate that images obtained using ShearWave™ Elastography are reproducible. The second is to compare ultrasound alone versus the combination of ultrasound and ShearWave™ Elastography for breast lesion diagnosis. The goal of the latter is to improve lesion classification in categories BI-RADS ® 3 and BI-RADS ® 4 in order to better direct patients towards clinical follow-up or biopsy.
"This clinical investigation is the largest trial ever undertaken by an ultrasound imaging company as the recruitment will involve a targeted 2300 breast lesion cases," explains Claude Cohen-Bacrie, co-founder and Scientific Director of SuperSonic Imagine.
"Today it is essential to obtain additional information on breast lesions to improve diagnosis. In an era of healthcare reform, being able to reduce the number of biopsies by correctly classifying lesions could save resources and spare women the anxiety and difficulty that surrounds invasive procedures. Better lesion classification also means improved diagnosis, which can lead to quicker and better treatment."
Transcranial ultrasound stimulation: A new frontier in noninvasive brain therapy